Navigation Links
Isis Pharmaceuticals Reports Data From a Phase 2 Study of Isis-CRP Rx in Patients with Rheumatoid Arthritis
Date:8/5/2013

bo-controlled, multiple-dose study in patients with RA who had chronically elevated CRP.  In this study, 51 patients received 100 mg, 200 mg or 400 mg dose of ISIS-CRPRx or placebo for 12 weeks.  Patients in the study treated with ISIS-CRPRx achieved substantial, dose-dependent reductions in CRP early in treatment that were prolonged through the treatment process.  Patients also experienced improvements in the signs and symptoms of RA, as measured by ACR20 and ACR50 scores.  These improvements correlated with reductions in CRP, but were not sufficiently greater than improvements observed in the placebo groups to justify further development of ISIS-CRPRx for RA. 

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Genzyme is also pursuing marketing approval of KYNAMRO in other markets.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding the development, activity, therapeutic potential and safety of ISIS-CRPRx.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intercept Pharmaceuticals to Present at the Wedbush Securities Life Sciences Management Access Conference
2. GW Pharmaceuticals Announces Results of MS Spasticity Study Confirming Sativex Has No Long-Term Negative Effect on Cognition
3. GW Pharmaceuticals plc Reports 2013 Third Quarter Financial Results
4. AcelRx Pharmaceuticals to Hold Second Quarter 2013 Financial Results Conference Call and Webcast on August 12, 2013
5. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018
6. OPTIMER PHARMACEUTICALS SHAREHOLDER ALERT: Levi & Korsinsky Investigates Possible Breaches of Fiduciary Duty by Board of Optimer Pharmaceuticals, Inc. in Connection with Sale of Company to Cubist Pharmaceuticals, Inc.
7. Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2013 Financial Results
8. Auxilium Pharmaceuticals, Inc, Announces Second Quarter 2013 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2013 Financial Results
10. Arisaph Pharmaceuticals Awarded Phase I STTR Grant To Develop Small Molecule Immune Modulators
11. Avion Pharmaceuticals, LLC, receives top accolades for trade and marketing achievements at the 11th Annual American Business Awards (The "Stevie Awards")
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the second quarter ended June 30, 2014, a ... the same period of 2013. During the ... were sold globally compared to 523 units in the ...
(Date:7/31/2014)... 2014 Second Quarter Total Revenue $2.0 billion; an increase of ... 4% for same store sales and 8% pro forma, excluding ... , 2014 Second Quarter GAAP EPS $0.37; Cash EPS $1.91, ... Operating Cash Flow $376 million; Adjusted Operating Cash Flow $500 ... Launched 17 new products in the U.S. year-to-date , ...
(Date:7/31/2014)... , 31 juli 2014 De Pfizer ... een rekruteringscampagne voor gezonde vrijwilligers van Japanse komaf voor ... gevestigde PCRU is één van twee onderzoekseenheden ... als ideaal levens te verbeteren door de ontdekking en ... de PCRU op zoek naar mannen en vrouwen van ...
Breaking Medicine Technology:HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 2HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 3HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 4HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 5HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 6HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 7HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 8HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 9HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 10HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 11HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 12Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 2Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 3Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 4Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 5Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 6Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 7Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 8Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 9Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 10Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 11Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 12Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 13Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 14Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 15Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 16Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 17Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 18Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 19Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 20Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 21Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 22Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 23Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 24Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 25
... PARSIPPANY, N.J., Sept. 15, 2011 Fidia Farmaceutici S.p.A. ... ® (sodium hyaluronate), an injectable treatment for knee ... and physical therapy are not enough, will be transferred ... 24, 2011.  Fidia Farmaceutici S.p.A. is the owner and ...
... September 15, 2011 Oramed Pharmaceuticals Inc. ... oral delivery systems, announced today that Ehud Arbit, M.D., ... present at the 8th Annual Israel Strategic Partner and ... Bristol-Myers Squibb Pharmaceutical Research Institute in Princeton, NJ on ...
Cached Medicine Technology:HYALGAN® (sodium hyaluronate) Commercial Rights Transfer Back to Fidia Farmaceutici S.p.A. 2Oramed Pharmaceuticals Chosen to Present at the 8th Annual Israel Strategic Partner and Venture Conference on September 22, 2011 2
(Date:7/31/2014)... Thousands of independent community pharmacists, ... have come together today to kick off ThoughtSpot ... , "ThoughtSpot 2014 is Good Neighbor Pharmacy’s annual ... to help their businesses thrive," stated AJ Caffentzis, ... long-standing commitment to independent community pharmacies, and at ...
(Date:7/31/2014)... 31, 2014 Web Programming Services, a ... certified internet marketing firm, has recently launched a new ... this service affordable for everyone, the company has announced ... , Web Programming Services has tailored the service ... brochure designing and likely expectations of the clients from ...
(Date:7/31/2014)... Agebc.com, a popular online shop of wedding dresses and women’s ... mother of the bride dresses . Aside from that, ... to 68% off. , “We are proud to enrich ... of the bride dresses. We launch the special offer to ... shop has received thousands of rave reviews from new and ...
(Date:7/31/2014)... new study by researchers at Sanford-Burnham Medical Research Institute ... convert existing cells in the pancreas into those cells ... published online July 31 in Cell Death and ... estimated 3 million people in the U.S., and over ... "We have found a promising technique for type 1 ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Quincy Bioscience, ... of brain health supplement Prevagen®, releases the second edition ... Marvelous Tips for Making Memories: Birth of a Grandchild. ... that offers exceptional memory-making tips and ideas for grandparents ... birth of a grandchild. Each concept published in the ...
Breaking Medicine News(10 mins):Health News:Good Neighbor Pharmacy’s ThoughtSpot Begins Today with Record Attendance 2Health News:Good Neighbor Pharmacy’s ThoughtSpot Begins Today with Record Attendance 3Health News:Web Programming Services Introduces Affordable Brochure Designing Service 2Health News:Mother of the Bride Dresses Now Available With Great Discounts at Agebc.com 2Health News:A new way to generate insulin-producing cells in Type 1 diabetes 2Health News:Quincy Bioscience Launches the Second E-Book of the Making Memories Series 2
... Surprising finding shows it reduces risk of death, recurrence , ... soy foods can help lower the risk of death and ... shows. , What,s more, the association between soy and a ... estrogen receptor-positive cancers and women taking tamoxifen, according to the ...
... ... that a new market research report is available ... for Interventional Cardiology 2009 (15 Countries) ... European market for interventional cardiology was valued at ...
... , ... new market research report is available in its catalogue: ... Players, and Important Trends) , http://www.reportlinker.com/p0167109/EMR-2010-Market-Analysis-ARRA-Incentives-Key-Players-and-Important-Trends.html ... Kalorama Information surveyed the market for electronic medical records. ...
... your cool with misbehaving children is a challenge. We all ... out at someone without thinking. A new study by ... parents with poorer working memory skills are less likely to ... "Angry, oppositional behavior in children is aversive and challenging to ...
... , Woodbury, N.Y., Dec. 8 On December 9 ... and Miami schools to perform the live nutrition rock concert, ... Dietitian and musician is appearing free to schools courtesy of ... programs. This interactive show promotes healthy eating by ...
... Dec. 8 Tipping Point Community, a charitable organization dedicated ... million donation from the Sergey Brin and Anne Wojcicki Foundation. ... Annual Awards Breakfast and is one of Tipping Point,s largest ... one-quarter of families are too poor to meet their basic ...
Cached Medicine News:Health News:Soy Beneficial for Breast Cancer Survivors: Study 2Health News:Soy Beneficial for Breast Cancer Survivors: Study 3Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 2Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 3Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 4Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 5Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 6Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 7Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 8Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 9Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 10Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 11Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 12Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 13Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 14Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 15Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 16Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 17Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 18Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 19Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 20Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 21Health News:Reportlinker Adds EMR 2010 (Market Analysis, ARRA Incentives, Key Players, and Important Trends) 2Health News:Reportlinker Adds EMR 2010 (Market Analysis, ARRA Incentives, Key Players, and Important Trends) 3Health News:Reportlinker Adds EMR 2010 (Market Analysis, ARRA Incentives, Key Players, and Important Trends) 4Health News:Reportlinker Adds EMR 2010 (Market Analysis, ARRA Incentives, Key Players, and Important Trends) 5Health News:Reportlinker Adds EMR 2010 (Market Analysis, ARRA Incentives, Key Players, and Important Trends) 6Health News:Breakfast BREAKS(R) 'Jump with Jill' Rockin' Nutrition Show Kicks off Tour in Florida Schools 2Health News:Tipping Point Community Announces $1 Million Gift at Third Annual Awards Breakfast 2
The Astigmatome makes precise and accurate cuts for astigmatism correction simply and safely. Depth: 500 to 600....
The Astigmatome makes precise and accurate cuts for astigmatism correction simply and safely. Depth: 500 to 700....
Designed to remove cell debris or tissue remnants from the retina....
... Medtronic presents the Streamline family of ... have taken the gold standard in temporary ... that make them easy to use and ... Streamline Temporary Pacing Leads are designed to ...
Medicine Products: